MSI testing in today's pathology lab: aiming for accuracy and breadth to facilitate optimal therapeutic decision making in oncology

28th October 2021, 4:30pm CEST

Microsatellite instability (MSI) is a well-established biomarker in the diagnosis and prognosis of malignancies and, more recently, a predictive biomarker of response to immunotherapy. Hence, an accurate definition of MSI status is crucial for treatment decisions and patient outcomes. In this webinar, we will review the root causes of MSI at the molecular level and the techniques that exist today in the pathologist toolbox to assess it, each with their advantages and disadvantages. Additionally, we will review current guidelines and recommendations for MSI testing in solid tumors. Finally, we will introduce VariantPlex, Invitae’s NGS research platform, now including expanded gene content and MSI reporting for more comprehensive decision making in oncology.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

I have read and understand the Privacy Notice*

Subscribe